| Literature DB >> 35844358 |
Asmaa E Ahmed1, Hassan Abol-Enein2, Amira Awadalla2, Heba El Degla3, Omar A El-Shehaby1.
Abstract
Purpose: Nephrolithiasis is a worldwide disease, and 4.7% of the patients may develop postoperative sepsis. Characterization of virulence genes of bacteria associated with renal stones is still lacking in the literature. The study aimed to investigate the virulence genes of the predominant stone bacterial isolate and their association with postoperative septic complications in patients treated with percutaneous nephrolithotomy (PCNL).Entities:
Keywords: S. aureus; antibiotic resistance; nephrolithiasis; percutaneous nephrolithotomy
Year: 2022 PMID: 35844358 PMCID: PMC9278723 DOI: 10.2147/IDR.S368852
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Patient Demographics
| Variable | |
|---|---|
| Patient’s characteristics | |
| Age, years (Mean ± SD) | 49.3±12.3 |
| Gender, no. pts (%) | |
| - Male | 77 (38.5) |
| - Female | 123 (61.5) |
| Comorbidities, no. pts (%) | |
| - Hypertension | 58 (29) |
| - Diabetes | 34 (17) |
| Septic patients, no. pts (%) | 8 (4) |
| Stones’ characteristic | |
| - Stone density (Mean ± SD), HU | 737.2±349.8 |
| - Stone size (Median, range), mm2 | 42.6 (2.8 −1680) |
| Operation time (minutes) (Mean ± SD) | 88.43±24.34 |
| Bleeding, no. pts (%) | |
| - Yes | 11 (5.5) |
| - No | 189 (94.5) |
| Tracts, no. pts (%) | |
| - Single | 180 (90) |
| - Multiple | 20 (10) |
| Method of disintegration, no. pts (%) | |
| - Ultrasound | 152 (76) |
| - Pneumatic | 27 (13.5) |
| - Combined | 21 (10.5) |
| Positive bacterial culture, no. pts (%) | |
| - Stone samples | 70 (35) |
| - Midstream urine samples | 60 (30) |
| Stone infection in relation to chemical composition, no. pts (%) | |
| - Calcium-based stones | 33/77 (42.8) |
| - Calcium oxalate | 27/60 (45) |
| - Calcium phosphate | 5/9 (55.5) |
| - Calcium oxalate/calcium phosphate | 1/8 (12.5) |
| Non-calcium-based stones | 35/110 (31.8) |
| - Uric acid | 28/94 (29.7) |
| - Cystine | 3/10 (30) |
| - Magnesium ammonium phosphate (Struvite) | 4/6 (66.6) |
| Mixed stones | 2/13 (15. 3) |
| - Calcium oxalate/Uric acid | 2/13 (15. 3) |
Abbreviations: no. pts, Number of patient; HU, Hounsfield units; SD, standard deviation; mm2, square millimeter.
Comparison Between Positive Bacterial Stone Culture and Midstream Urine Culture
| Type of Bacteria | Positive Midstream Urine Culture, n (%) | Positive Stone Culture, n (%) | Isolates from Midstream Urine Culture Versus Stone Culture | ||
|---|---|---|---|---|---|
| Similar | Different | Sterile | |||
| 34 (56.6) | 10 (14.2) | 8 | 0 | 2 | |
| 12 (20) | 30 (42.8) | 12 | 6 | 12 | |
| 8 (13.3) | 2 (2.8) | 2 | 0 | 0 | |
| 4 (6.6) | 10 (14.2) | 4 | 2 | 4 | |
| 2 (3.3) | 10 (14.2) | 0 | 2 | 8 | |
| 0 | 8 (11.4) | 0 | 2 | 6 | |
| Total, n (%) | 60 (100) | 70 (100) | 26 (37.1) | 12 (17.1) | 32 (45.7) |
Note: Values are expressed as n (%).
Abbreviation: n=Number.
The Distribution of the Types of Bacterial Stone Culture in Relation to Its Chemical Composition
| Stone Culture n= 70 | |||||||
|---|---|---|---|---|---|---|---|
| Chemical Composition | |||||||
| Calcium-based stone (n=33) | 4 | 18 | 1 | 3 | 4 | 3 | 0.32 |
| - Calcium oxalate (n=27) | 3 | 14 | 1 | 2 | 4 | 3 | |
| - Calcium phosphate (n=5) | 1 | 3 | 0 | 1 | 0 | 0 | |
| - Calcium oxalate/calcium phosphate (n=1) | 0 | 1 | 0 | 0 | 0 | 0 | |
| Non-calcium-based stone (n= 35) | 6 | 11 | 0 | 7 | 6 | 5 | |
| - Uric acid (n=28) | 4 | 9 | 0 | 7 | 5 | 3 | |
| - Cystine (n=3) | 1 | 1 | 0 | 0 | 1 | 0 | |
| - Magnesium ammonium phosphate (Struvite) (n=4) | 1 | 1 | 0 | 0 | 0 | 2 | |
| Mixed stone (n=2) | 0 | 1 | 1 | 0 | 0 | 0 | |
| - Calcium oxalate/Uric acid (n=2) | 0 | 1 | 1 | 0 | 0 | 0 | |
Note: *Fisher’s exact test.
Abbreviation: n, Number.
Distribution of Virulence Genes Among S. aureus Strains and Among Septic and Non-Septic Patients
| Distribution of Virulence Genes (n=30) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hemolysine Genes | Panton-Valentine Leukocidin Gene | Adhesion Genes | Enterotoxin Genes | ||||||
| Positive, n (%) | 28 (93.3) | 17 (56.7) | 17 (56.7) | 22 (73.3) | 7 (23.3) | 7 (23.3) | 5 (16.7) | 0 | 0 |
| Negative, n (%) | 2 (6.7) | 13 (43.3) | 13 (43.3) | 8 (26.6) | 23 (76.7) | 23 (76.7) | 25 (83.3) | 30 (100) | 30 (100) |
| Septic patients (n=7) | 7 (25) | 7 (41.1) | 7 (41.1) | 7 (31.8) | 7 (100) | 7 (100) | 5 (100) | 0 | 0 |
| Non-septic patients | 21 (75) | 10 (58.8) | 10 (58.8) | 15 (68.1) | 0 | 0 | 0 | 0 | 0 |
| 1.0 | 0.01* | 0.01* | 0.1 | ≤0.001* | ≤0.001* | ≤0.001* | - | - | |
Notes: Values are expressed as n (%). p values were obtained from Fisher’s exact test. *Statistically significant.
Abbreviations: hla, Hemolysine a; hlb, Hemolysin b; seb, staphylococcal enterotoxin b; sea, staphylococcal enterotoxin a; sec, staphylococcal enterotoxin c; pvl, Pantone-Valentine leukocidin; can, collagen binding protein; fnbA, fibronectin binding proteins A; fnbB, fibronectin binding proteins B; n, number.
Relation of Antibiotic Resistance to Virulence Genes of S. aureus
| Antibiotic Genes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vancomycin | 7 (25) | 0 (0) | 4 (23.5) | 3 (23) | 4 (23.5) | 3 (23) | 7 (31.8) | 0 (0) | 0 (0) | 7 (30.4) | 0 (0) | 7 (30.4) | 0 (0) | 7 (28) |
| 1.0 | 0.5 | 0.5 | 0.1 | 0.02* | 0.02* | 0.5 | ||||||||
| Cefoxitin | 9 (32.1) | 2 (100) | 9 (52.9) | 2 (15.3) | 7 (41.1) | 4 (30.7) | 9 (40.9) | 2 (25) | 5 (71.4) | 6 (26) | 5 (71.4) | 6 (26) | 5 (100) | 6 (24) |
| 0.2 | 0.1 | 0.8 | 0.3 | 0.004* | 0.004* | 0.008* | ||||||||
| Amoxicillin/Clavalanic Acid | 9 (32.1) | 0 (0) | 9 (52.9) | 0 (0) | 9 (52.9) | 0 (0) | 9 (40.9) | 0 (0) | 7 (100) | 2 (8.6) | 7 (100) | 2 (8.6) | 5 (100) | 4 (16) |
| 1.0 | 0.002* | ≤0.001* | 0.01* | ≤0.001* | ≤0.001* | 0.001* | ||||||||
| Nitrofurantoin | 5 (17.8) | 0 (0) | 2 (11.7) | 3 (23) | 2 (11.7) | 3 (23) | 5 (22.7) | 0 (0) | 0 (0) | 5 (21.7) | 0 (0) | 5 (21.7) | 0 (0) | 5 (20) |
| 1.0 | 0.6 | 0.6 | 0.2 | 0.3 | 0.3 | 0.5 | ||||||||
| Norfloxacin | 15 (53.5) | 2 (100) | 13 (76.4) | 4 (30.7) | 11 (64.7) | 6 (46.1) | 13 (59) | 4 (50) | 7 (100) | 10 (43.4) | 7 (100) | 10 (43.4) | 5 (100) | 12 (48) |
| 0.4 | 0.02* | 0.4 | 0.6 | 0.01* | 0.01* | 0.052 | ||||||||
| Cefaclor | 9 (32.1) | 0 (0) | 9 (52.9) | 0 (0) | 7 (41.1) | 2 (15.3) | 9 (40.9) | 0 (0) | 5 (71.4) | 4 (17.3) | 5 (71.4) | 4 (17.3) | 5 (100) | 4 (16) |
| 0.6 | 0.001* | 0.002 | 0.01* | 0.003* | 0.003* | 0.001* | ||||||||
| Gentamicin | 8 (28.5) | 0 (0) | 5 (29.4) | 3 (23) | 5 (29.4) | 3 (23) | 8 (36.3) | 0 (0) | 3 (42.8) | 5 (21.7) | 3 (42.8) | 5 (21.7) | 3 (60) | 5 (20) |
| 1.0 | 0.5 | 0.3 | 0.07 | 0.6 | 0.6 | 0.2 | ||||||||
| Cephalotin | 20 (71.4) | 0 (0) | 13 (76.4) | 7 (53.8) | 17 (100) | 3 (23) | 16 (72.7) | 4 (50) | 7 (100) | 13 (56.5) | 7 (100) | 13 (56.5) | 5 (100) | 15 (60) |
| 0.1 | 0.2 | ≤0.001* | 0.3 | 0.06 | 0.06 | 0.1 | ||||||||
| Ampicillin–sulbactam n=5 | 5 (17.8) | 0 (0) | 5 (29.4) | 0 (0) | 5 (29.4) | 0 (0) | 5 (22.7) | 0 (0) | 3 (42.8) | 2 (8.6) | 3 (42.8) | 2 (8.6) | 3 (60) | 2 (8) |
| 1.0 | ≤0.001* | ≤0.001* | 0.4 | ≤0.001* | ≤0.001* | 0.003* | ||||||||
| Levofloxacin | 8 (28.5) | 0 (0) | 6 (35.2) | 2 (15.3) | 6 (35.2) | 2 (15.3) | 6 (27.2) | 2 (25) | 2 (28.5) | 6 (26) | 2 (28.5) | 6 (26) | 2 (40) | 6 (24) |
| 1.0 | 0.1 | 0.1 | 1.0 | 0.04* | 0.04* | 0.7 | ||||||||
Notes: Values are expressed as n (%). p values were obtained from Fisher’s exact test. *Statistically significant.
Abbreviations: hla, hemolysine a; hlb, hemolysine b; seb, staphylococcal enterotoxin b; pvl, Pantone-Valentine leukocidin; can, collagen binding protein; fnbA, fibronectin binding proteins A; fnbB, fibronectin binding proteins B; n, number; (+), presence of gene; (-), absence of gene.